We will seek to understand when a precision medicine approach will be beneficial and when it is unlikely to be so. If we can increase our understanding, then we can better focus on increasing the efficiency of precision medicine based drugs.

Ido Wolf.JPG
Ido Wolf
Head, Oncology Division, Tel Aviv Medical Center, Tel Aviv, Israel

Molecular Tests in the Clinic: Where Do We Stand in 2017?
Precision medicine is being perceived by patients and physicians alike as 
a new standard of care in oncology. However, the definition of precision medicine is vague and the evidence regarding its benefit in the clinic are scarce and often controversial. In his talk, Prof. Wolf will mostly refer to genomic testing and use an evidence-based approach to discuss if and how genomic tests should be routinely used in the clinic.  Another topic to be discussed is the use of data generated routinely in the clinic, as an accelerator of basic science research.

Michael Heuser 178x219.jpg
Michael Heuser
Heisenberg Chair for Molecular Therapies in Hematology, Hannover Medical School, Hannover, Germany

Precision Medicine in the Academic Setting
How precise should precision medicine be? One patient has several targets and tumor cells may rapidly evade the selective pressure of a specific inhibitor. Michael Heuser will discuss what can be achieved with a molecularly targeted approach in a concerted action of the national and global leukemia community. 

Pia Raanani.jpg
Pia Raanani
Head of The Hematology Division in Rabin Medical Center, Tel Aviv, Israel

Personalized Medicine in Chronic Myeloid Leukemia (CML) in 2018 – Does It Exist? A Clinician’s Perspective
Unlike its (controversial) place in the treatment of solid tumors, personalized medicine in hemato-oncology is still in its infancy.
Bearing this in mind, we ask ourselves whether there is a role for precision medicine in CML at all and if yes, what are its implications - Scientific? Clinical? Both?
The lecture will concentrate mainly on the clinical aspects of personalized medicine in CML. Cutting edge objectives in CML in 2018 and their applications for a personalized approach will be discussed including: the various options for first line treatment, adherence to treatment, treatment free remission (cure?) and treatment discontinuation, age adjusted treatment according to: therapeutic goals, comorbidities and adverse events, the issue of pregnancy in young CML female patients, and finally, the role of bone marrow transplantation, once the leading approach in CML, in the era of targeted therapies and precision medicine.

Ulrich Keilholz
Acting Director, Charité Comprehensive Cancer Center, Berlin, Germany

To download the full programme, click here.